If approved, garadicimab will slot into CSL's product line alongside two C1 esterase inhibitor medicines, namely Berinert which is administered by intravenous injection to treat HAE attacks ...
If approved, garadicimab will slot into CSL’s product line alongside two C1 esterase inhibitor medicines, namely Berinert, which is administered by intravenous injection to treat HAE attacks ...
It recently completed a $156 million expansion project which included the installation of a second pre-filled syringe line and expansion of its warehouse. All of this has greatly benefited CSL ...
The top line decreased 0.4% year over year. For 2024, CSL reported net revenues of $5 billion, which increased 9.1% year over year. For the year, the company’s adjusted earnings were $20.20 per ...
Hosted on MSN1mon
Carlisle Q4 Earnings Miss, Construction Materials Sales Up Y/YCarlisle’s total revenues of $1.12 billion missed the consensus estimate of $1.15 billion. The top line decreased 0.4% year over year. For 2024, CSL reported net revenues of $5 billion, which ...
Learn More The CSL Ltd (ASX: CSL) share price is down 1.6% to $255.51 per share on Monday. The ASX 200 biotech is in the red today because its shares have begun trading ex-dividend. The CSL share ...
Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with CSL Seqirus (ASX:CSL) for the exclusive rights to commercialize NEXLETOL ® (bempedoic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback